DRUG
Secretin
Native hormone
Status
Completed
Phase
Not applicable
Enrollment
25
Locations
1
Results
Not posted
Publications
1
Study summary
As of last year, new insight into the function of secretin was brought about as rodent studies showed secretin to possess potential body weight-regulating effects. In these studies, secretin was shown to increase non-shivering thermogenesis in brown adipose tissue (BAT), decrease meal size and promote meal discontinuation. The mechanisms behind these regulatory effect of secretin on energy homeostasis are unclear,
Secretin was - as the first hormone - identified in 19021, but was not isolated until the 1960s. Secretin is produced in and secreted form small intestinal S cells. In the 1970s, the primary endocrine effects of secretin were unequivocally confirmed, namely potentiation of bicarbonate and pepsin secretion from the pancreas as well as stimulation of bile production in the liver. In the 1990s, the biosynthesis of secretin was delineated and its receptor was discovered. In the 2000s the pancreatic regulation of intestinal pH was shown to be secretin-mediated. As of last year, new insight into the function of secretin was brought about as rodent studies showed secretin to possess potential body weight-regulating effects. In these studies, secretin was shown to increase non-shivering thermogenesis in brown adipose tissue (BAT), decrease meal size and promote meal discontinuation. The primary aim of this study is to evaluate the effect of a 5-hour intravenous infusion with the naturally occurring hormone secretin on ad libitum food intake (primary endpoint) compared to a double-blinded placebo (isotonic saline) infusion in 25 healthy young males.
Interventions
DRUG
Native hormone
OTHER
Saline
Timeline
First posted
Nov 3, 2020
Study start
Mar 1, 2020
Primary completion
Sep 29, 2020
Study completion
Sep 29, 2020
Results posted
Not reported
Registry updated
Nov 5, 2020
Outcomes
Food intake on ad libitum meal
Time frame · 300 minutes
Kilojoule
Duration of ad libitum meal
Time frame · 300 minutes
Duration in minutes
Water intake during ad libitum meal
Time frame · 300 minutes
mL
resting energy expenditure
Time frame · Baseline, 90 minutes and 270 minutes
Indirect calorimetry of respiration
Supraclavicular Brown adipose activity
Time frame · -15 to 15 , 90 and 270 minutes
Evaluated by neck skin temperature assessed using a non-invasive thermal imaging camera)
Appetite and satiety sensations (assessed by VASs),
Time frame · Every 15 minutes after infusion, until time-point 90, hereafter every 30 minutes
Visual analogue scales with a scale of 1-10 (Direction of scale varies)
Heart rate
Time frame · every 15 minutes from from -15 to 300 minutes
heart rate .
systolic blood pressure
Time frame · every 15 minutes from from -15 to 300 minutes
Systolic blood pressure
Diastolic blood pressure
Time frame · every 15 minutes from from -15 to 300 minutes
Diastolic blood pressures
Gallbladder motility
Time frame · Timepoint -30, 10,20,45,60,75,90,120,210,300 minutes
Gallbladder motility measured by Ultrasound
Eligibility
Inclusion Criteria: * Age between 18 and 75 years * Body mass index between 18.5 and 27.5 kg/m2 * Informed consent * Body weight above 50 kg Exclusion Criteria: * Anaemia (blood haemoglobin below normal range) * Known liver disease and/or alanine aminotransferase and/or aspartate transaminase \> 2 times upper normal values * Nephropathy (serum creatinine above normal range and/or albuminuria) * Clinically significant kidney function impairment or other laboratory findings leading to the diagnosis of clinically relevant disorders (thyroid dysfunction, anaemia etc) * Any physical or psychological condition that the investigators feel would interfere with trial participation
Study locations
Denmark. Showing up to 24 locations stored in the fast local snapshot.
Herlev- Gentofte Hospital, Center for Clinical Metabolic Research
Hellerup, Copenhagen, Denmark
Related trials
Mayo Clinic · Exocrine Pancreatic Insufficiency · Chronic Pancreatitis
Phase 4
Recruiting
24
2026-07
Erasmus Medical Center · Liver Transplantation
Phase 1 / Phase 2
Enrolling by invitation
20
2026-06
Children's Hospital Medical Center, Cincinnati · Pancreatitis · Diabetes Mellitus
Phase 4
Enrolling by invitation
195
2026-03
University of California, Los Angeles · Anorexia in Adolescence
Not applicable
Recruiting
10
2026-02
M.D. Anderson Cancer Center · Pancreatitis
Not applicable
Recruiting
2,345
2025-10
Johns Hopkins University · Pancreas Cancer · Peutz-Jeghers Syndrome (PJS)
Phase 3
Recruiting
9,000
2025-10
The University of Texas Health Science Center at San Antonio · Post Bariatric Surgery · Gastric Bypass
Early Phase 1
Recruiting
200
2025-09
Adenocyte, LLC · IPMN, Pancreatic · Pancreas Cancer
Not applicable
Enrolling by invitation
500
2025-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.